The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Infotagion Update

8 Apr 2020 09:37

RNS Number : 2064J
Iconic Labs PLC
08 April 2020
 

 

 

8 April 2020

 

 

Iconic Labs Plc ("Iconic Labs" or the "Company")

Media Launch of Infotagion is Viewed by 1million readers

 

Iconic Labs Plc (LSE:ICON) (the "Company"), a multi-divisional new media and technology business, announces the successful launch of Infotagion by reaching 1million readers.

 

The Company announced last week that, in partnership with Damian Collins MP, former Chair of the Parliamentary Committee on Culture, Media and Sport, it had established a service to counter the dissemination of incorrect information, in particular through social media, that relates to the Covid-19 pandemic and its related economic and social effects.

 

In just a matter of days the media launch resulted in more than 70 pieces of individual news covered by the UK's major news outlets including the BBC, ITV, Daily Mail, WIRED, Yahoo, radio and local and specialist news sites.

 

The phenomenal success of the media launch meant that at least 1million readers viewed the news; it was shared across social media nearly three thousand times and also verified by Facebook and Twitter.

 

The full list of media coverage surrounding Infotagion can be found here: https://www.iconiclabs.co.uk/infotagion-the-battle-against-disinformation/

 

In addition to this the group of supporters within governments and organisations around the world continues to grow and the full list is updated on the Infotagion website.

 

The company has been approached by a number of global organisations about using the Infotagion platform and data. The company looks forward to updating the market with the progress of these plans.

 

John Quinlan, Chief Executive Officer of Iconic Labs, said: ""We are delighted with the launch of Infotagion. To receive such a response in such a short period of time just goes to show how important this service is to the public. The support has been unprecedented and the platform is growing day by day. For Twitter and Facebook to verify us so quickly also shows a level of cooperation and trust from them and we thank them for their support. We plan to keep growing this platform and increasing the awareness of what Infotagion and Iconic Labs can achieve."

 

Social media is providing to be a very powerful and important asset to our communities in the current crisis. In particular it provides one the most effective means by which people can maintain essential interaction with others, and preserve communities, during this period of social distancing and isolation.

However, there is another side in that social media is one of the primary forums in which disinformation, whether circulated innocently or deliberately, is prevalent. We are therefore very pleased to be able to play a role in helping to counter disinformation about the current Covid-19 pandemic by bringing our expertise and skills to bear on the problem."

 

Infotagion

 

The core of the service is a website (www.infotagion.co.uk ) on which users post screenshots of information which they have received from social media or elsewhere. The submitted information is checked by a team organised by Mr Collins, which includes experts from, inter alia, the WHO and Parliament.

 

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

 

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

 

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDSSDSAAESSEDL
Date   Source Headline
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023
24th Oct 20235:31 pmRNSChange of Auditor
17th Oct 20237:51 amRNSConversion of Securities
13th Oct 202311:32 amRNSAnnouncement of the Completion of CVA
13th Oct 202311:30 amRNSConversion of Securities
29th Sep 20238:01 amRNSTotal Voting Rights
22nd Sep 20239:40 amRNSConversion of Securities
18th Sep 20236:27 pmRNSConversion of Notes – Replacement
18th Sep 20237:37 amRNSConversion of Securities
12th Sep 20238:45 amRNSStatement re CVA
4th Sep 202312:02 pmRNSConversion of Securities
31st Aug 20237:21 amRNSTotal Voting Rights
25th Aug 20234:49 pmRNSResult of AGM
18th Aug 20237:51 amRNSConversion of Securities
14th Aug 20237:59 amRNSIssue of Debt
8th Aug 20232:58 pmRNSPublication of a Prospectus
4th Aug 20234:19 pmRNSNotice of AGM
30th Jun 20239:12 amRNSTotal Voting Rights
2nd Jun 20231:20 pmRNSIssue of Equity
28th Apr 202310:35 amRNSTotal Voting Rights
12th Apr 20238:13 amRNSConversion of Securities
31st Mar 20233:11 pmRNSTotal Voting Rights
31st Mar 20231:59 pmRNSHalf-year Report
29th Mar 20232:05 pmRNSSecond Price Monitoring Extn
29th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Mar 20237:42 amRNSConversion of Securities
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 202311:48 amRNSSubscription of Convertible Notes
21st Mar 202311:05 amRNSSecond Price Monitoring Extn
21st Mar 202311:00 amRNSPrice Monitoring Extension
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
20th Mar 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.